Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV: early-phase trial registry
109 of 304 indexed HIV trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #27 of 28,707 conditions by registered trial count.
304 US clinical trials · 109 currently recruiting · #27 of 28,707 conditions by registered trial count
HIV: 304 US clinical trials tracked, 109 recruiting.
HIV is the subject of 304 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 24 of these trials.
Enrollment posture brief
Registry condition hiv
OPEN 109 | RECR 36% | LATE 25 | EARLY 64 | RANK #27 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
HIV lists 109 open slots (36% of 304 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV recruits in line with its size-band peers.
109 of 304 indexed trials (35.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of HIV trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 24 of 304 trials (7.9%). 115 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV enrolment sits around 100 participants.
Median target enrolment is 100 among the 304 trials that report a genuine target (sentinel values excluded). 142 of those (46.7%) plan for fewer than 100 participants.
-
HIV research is mostly interventional.
252 interventional and 52 observational studies make up this index (82.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
304 total, page 5 of 7
Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings
Hunter College of City University of New York
NCT02390908
Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01089114
Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
Bristol-Myers Squibb
NCT01335698
Acceptability, Feasibility, and Preliminary Impact of a Web-based, HIV Prevention Toolkit With Cisgender Male Couples in Lima, Peru
Florida International University
NCT05873855
Body Image in Youth With HIV
St. Jude Children's Research Hospital
NCT01673750
Antiretroviral Therapy Selection: Comparing HIV Clinical Guidelines With HIV-ASSIST, an Online Decision-support Tool
Johns Hopkins University
NCT04080765
Transitioning HIV+ Adolescents to Adult Care: Exploring Adolescent and Adult Medicine Clinics Role in the Process
University of North Carolina, Chapel Hill
NCT02785302
An HIV Intervention for Black Men at Risk - The Enhanced Sexual Health Intervention for Men (ES-HIM)
University of California, Los Angeles
NCT01641146
HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)
University of Pennsylvania
NCT03348813
Internet-based HIV/STI Prevention for Young MSM Receiving HIV Testing
University of Illinois at Chicago
NCT00968188
Suppression of HIV 1 RNA in People Living With HIV
Johns Hopkins University
NCT02363387
EPIC-P Intervention
University of Connecticut
NCT04193787
Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Stanford University
NCT01985399
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01172535
Health Improvement for Baltimore Youth
Johns Hopkins University
NCT02624193
Positive Lifestyles Using Safety
Yale University
NCT00836290
Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients
University of Colorado, Denver
NCT02610374
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
University of Maryland, Baltimore
NCT03823911
To Reach Unrestricted Services for Transgender Women
University of Central Florida
NCT03877497
Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
Icahn School of Medicine at Mount Sinai
NCT02626949
ARV Concentrations in Hair
University of North Carolina, Chapel Hill
NCT02768779
Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients
Duke University
NCT02405026
A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM
RAND
NCT03432819
MyPEEPS Mobile for Young Transgender Men
Columbia University
NCT05424718
Mobile Health Application to Improve HIV Medication Adherence
Rhode Island Hospital
NCT02676128
American Indian and Alaska Native Men Who Have Sex With Men HIV & Substance Abuse Research
University of Washington
NCT03049904
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
Gilead Sciences
NCT02071082
Onboarding Positives and PrEP Users to Engage Negatives (OPPEN): Peer-driven Education to Link YMSM of Color to PrEP
University of California, San Diego
NCT05356910
Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls
University Hospitals Cleveland Medical Center
NCT02324179
Zenyth: Motivational Interviewing-based Telehealth Intervention for Bacterial Sexually Transmitted Infection Screening
University of Michigan
NCT06100250
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
Indiana University
NCT00668395
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences
NCT00869557
Pre-Exposure Prophylaxis in YMSM
University of North Carolina, Chapel Hill
NCT01033942
Evaluating a Real-Time, Remote Monitoring System for Home-Based HIV Testing
Brown University
NCT02876926
Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)
University of California, San Francisco
NCT05152953
Cell Phone Technology Targeting ART Adherence and Drug Use
University of California, Los Angeles
NCT01884233
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
Yale University
NCT00798538
Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk
Lisa Haddad
NCT02357368
Antiplatelet Therapy in HIV
NYU Langone Health
NCT02559414
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Gilead Sciences
NCT01967940
A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
University of Maryland, Baltimore
NCT00344461
Evaluating Factors That Impact Loss to Follow-up Among Postpartum HIV-infected Women in Mississippi
University of Mississippi Medical Center
NCT01190605
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
Friends Research Institute
NCT00856323
Relationship of Exercise, Sleep, and Inflammation Markers in People Living With HIV
Christine Horvat Davey
NCT04946994
Eliminating Hepatitis C Virus
Icahn School of Medicine at Mount Sinai
NCT03401697
Zinc Supplementation and Cardiovascular Risk in HIV
Grace McComsey
NCT02856269
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
Philadelphia Fight
NCT02367807
Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms
CONRAD
NCT02569697
Intervention for Newly Diagnosed Youth With HIV
University of North Carolina, Chapel Hill
NCT00510237
Health Improvement Project - Providence
The Miriam Hospital
NCT02886234
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 32 |
| Phase 2 | 32 |
| Phase 3 | 12 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV page
304 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 109 HIV trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV condition card totals 304 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.